Key result
Higher MVPABMI linked to ~2.1-fold higher postoperative metastasis risk in resected stage I lung adenocarcinoma.
Why the study?
Recent animal models suggest cardiac function may relate to clinical outcomes in lung adenocarcinoma metastasis, prompting a search for a cardiac function-associated predictive index for postoperative metastasis.
Does the preoperative mitral valve peak A velocity to body mass index ratio (MVPABMI) predict postoperative metastasis and disease-free survival in patients undergoing thoracoscopic resection for stage I lung adenocarcinoma?
Cohort (n=207)
No
Does the preoperative mitral valve peak A velocity to body mass index ratio (MVPABMI) predict postoperative metastasis and disease-free survival in patients undergoing thoracoscopic resection for stage I lung adenocarcinoma?
Preoperative mitral valve peak A velocity adjusted for BMI (MVPABMI) may serve as a novel echocardiographic predictor of postoperative metastasis and reduced disease-free survival in patients with resected stage I lung adenocarcinoma, particularly in the solid subtype.
Answers are grounded in this paper and cite their sources.
May support preoperative metastasis risk stratification; hypothesis-generating and should not yet change practice.
Background: According to recent animal models for lung adenocarcinoma metastasis, cardiac function may be related to the clinical outcome. The aim of this study is to identify a predictable index for postoperative metastasis (POM) that is associated with cardiac function. Methods. Two hundred and seven consecutive patients who underwent thoracoscopic resection for stage I lung adenocarcinoma were included. Disease-free survival (DFS), overall survival (OS), and patients’ clinical and pathological characteristics were analyzed. Results. Among the 207 patients, 17 cases demonstrated metastasis, 110 cases received a preoperative echocardiogram, and six cases had POM. Mitral valve peak A velocity, which is one of the left ventricular diastolic function parameters affected by BMI (MVPABMI), was associated with a negative factor for POM (hazard ratio (HR): 2.139, p = 0.019) and a poor 5-year DFS in the above median (100% vs. 87%, p = 0.014). The predictable rate increased from 30.7% to 75% when the MVPABMI was above the median = 3.15 in the solid subtype). Conclusions. MVPABMI is a novel index for POM prediction in early-stage lung adenocarcinoma. This is a pilot study and the first attempt at research to verify that the diastole and the BMI may be associated with POM in early-stage lung adenocarcinoma.
No takes yet. Share an insight, caveat, or question.
Chiang et al. (2023) conducted a cohort in Stage I lung adenocarcinoma undergoing thoracoscopic resection (n=207). Mitral valve peak A velocity adjusted by body mass index (MVPABMI) vs. MVPABMI at or below median (3.15) was evaluated on Postoperative metastasis (POM) (HR 2.139, p=0.019). Mitral valve peak A velocity adjusted by BMI (MVPABMI) was associated with increased postoperative metastasis in resected stage I lung adenocarcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: